Co-existent endometrial and ovarian carcinoma: molecular and pathological features define low risk entity
FIGO IA3 criteria identify a subset of co-existent endometrial and ovarian carcinomas with excellent outcomes. However, incorporating molecular features into the definition enables greater prognostic discernment and supports the inclusion of patients with a broader range of pathologic features with indolent disease (increased from 20% to 49% of the cohort, 0 recurrences) who may be candidates for treatment de-escalation.
Authors
- Derek S. Chiu (ORCID: https://orcid.org/0000-0002-7591-4881)
- Amy Lum (ORCID: https://orcid.org/0000-0002-9236-2492)
- Michael S. Anglesio (ORCID: https://orcid.org/0000-0003-1639-5003)
- C. Blake Gilks (ORCID: https://orcid.org/0000-0001-7889-8250)
- Jessica N. McAlpine (ORCID: https://orcid.org/0000-0001-6003-485X)
- Amy Jamieson (ORCID: https://orcid.org/0000-0002-3210-9102)
- Mehrane Nazeran
- Marcel Grube (ORCID: https://orcid.org/0000-0002-6609-8827)
- Niki Boyd
- Andrea Neilson
- Janine Senz (ORCID: https://orcid.org/0009-0007-5475-4974)
- David G. Huntsman (ORCID: https://orcid.org/0000-0003-4934-3322)
- Jutta Huvila
- Samuel Leung
- Stefan Kommoss
Institutions
- University of British Columbia (CA)
- University of Turku (FI)
- Turku University of Applied Sciences (FI)
- University Children's Hospital Tübingen (DE)
Publication Details
- Journal
- International Journal of Gynecological Cancer
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1016/j.ijgc.2025.101957
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.06
Funders
- Vancouver Coastal Health Research Institute
- BC Cancer Foundation